Table VI.

Impact of Individual Donor KIR B Genes on LFS and Relapse in C2/C2 Recipients

A. All Transplants
Donor KIR Group	n	RR	P	n	RR	P
		LFS			Relapse
KIR A/A	74	1.00		77	1.00
KIR B/x with 2DS2+	113	1.09 (0.73–1.63)	0.69	119	1.17 (0.67–2.07)	0.58
KIR B/x with 2DS5+	75	1.22 (0.78–1.92)	0.38	76	0.89 (0.48–1.65)	0.72
KIR B/x with 2DL2+	112	1.07 (0.71–1.61)	0.74	117	1.16 (0.65–2.08)	0.61
KIR B/x with 2DS1+	92	1.16 (0.75–1.80)	0.51	96	0.99 (0.56–1.77)	0.97
KIR B/x with 3DS1+	90	1.10 (0.72–1.69)	0.65	94	1.06 (0.60–1.87)	0.84
KIR B/x with 2DS3+	60	1.26 (0.75–2.10)	0.38	63	1.06 (0.56–2.01)	0.85
KIR B/x with 2DL5+	117	1.09 (0.73–1.61)	0.68	121	0.98 (0.57–1.69)	0.93

B. HLA Matched
Donor KIR Group	n	RR	P	n	RR	P
		LFS			Relapse
KIR A/A	37	1.00		39	1.00
KIR B/x with 2DS2+	66	1.13 (0.63–2.02)	0.68	68	0.94 (0.43–2.05)	0.88
KIR B/x with 2DS5+	36	1.26 (0.62–2.54)	0.52	36	0.81 (0.31–2.12)	0.66
KIR B/x with 2DL2+	65	1.08 (0.60–1.95)	0.79	66	0.86 (0.39–1.91)	0.71
KIR B/x with 2DS1+	45	1.25 (0.63–2.47)	0.52	46	0.90 (0.37–2.21)	0.82
KIR B/x with 3DS1+	44	1.15 (0.58–2.28)	0.69	45	1.00 (0.41–2.43)	0.99
KIR B/x with 2DS3+	33	0.95 (0.43–2.13)	0.91	34	0.85 (0.34–2.12)	0.72
KIR B/x with 2DL5+	60	1.18 (0.63–2.20)	0.60	61	0.82 (0.36–1.84)	0.63

C. HLA Mismatched
Donor KIR Group	n	RR	P	n	RR	P
		LFS			Relapse
KIR A/A	37	1.00		38	1.00
KIR B/x with 2DS2+	47	1.57 (0.71–3.48)	0.27	51	1.62 (0.56–4.72)	0.38
KIR B/x with 2DS5+	39	1.07 (0.49–2.33)	0.86	40	0.92 (0.36–2.36)	0.86
KIR B/x with 2DL2+	47	1.53 (0.69–3.40)	0.30	51	1.81 (0.59–5.55)	0.30
KIR B/x with 2DS1+	47	1.18 (0.56–2.47)	0.67	50	1.26 (0.51–3.08)	0.62
KIR B/x with 3DS1+	46	1.21 (0.58–2.49)	0.61	49	1.27 (0.52–3.08)	0.60
KIR B/x with 2DS3+	27	2.33 (0.73–7.47)	0.15	29	1.31 (0.42–4.08)	0.64
KIR B/x with 2DL5+	57	1.13 (0.58–2.24)	0.72	60	1.09 (0.45–2.62)	0.85